SynthesisScientific reports2024
A systematic review of circulating IP-10/CXCL10 in patients with Plasmodium infections in relation to disease severity.
Synthesis in Scientific reports, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Integration of bulk RNA-seq and scRNA-seq reveals cell subsets and gene signatures associated with Glaesserella parasuis infection.BMC genomics · 2026Article
- Neurovascular Pathophysiology and Emerging Biomarkers in Cerebral Malaria: An Integrative Perspective.Neurology international · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Interferon γ-induced protein 10 kDa (IP-10) or C-X-C motif chemokine 10 (CXCL10) is produced and secreted from specific leukocytes such as neutrophils, eosinophils, and monocytes, which play key roles in the immune response to Plasmodium infections. This systematic review aimed to collate and critically appraise the current evidence on IP-10 levels in malaria patients. It provided insights into its role in malaria pathogenesis and potential as a biomarker for Plasmodium infections and disease severity. The protocol for this systematic review was registered in PROSPERO (number CRD42024556087). A comprehensive literature search was conducted across multiple databases, including Embase, PubMed, Scopus, Ovid, ProQuest, and MEDLINE, to identify relevant studies examining the role of IP-10 in patients with Plasmodium infections. A narrative synthesis was applied to summarize key findings and to provide an overview of the relationship between IP-10/CXCL10 levels and Plasmodium infection and disease severity. A total of 1933 records were identified, and 26 studies were included in the synthesis. The studies collectively indicated that IP-10 levels are elevated in patients with Plasmodium infections compared to healthy or non-malarial controls. Most studies reported that increased IP-10 levels were associated with increased disease severity. However, a few studies found no significant difference or decreased levels in patients with severe Plasmodium infections compared to those with uncomplicated or mild malaria. Additionally, several studies indicated that IP-10 levels were elevated in cerebral malaria. The systematic review suggests that IP-10 is elevated in patients with Plasmodium infections. However, the variability in findings across different studies regarding the association between IP-10 and severe malaria, particularly cerebral malaria, highlights the need for further comprehensive studies. Addressing confounding factors will be crucial in future research to better understand the role of IP-10 in Plasmodium infections and the pathogenesis of severe disease.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.